+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Nasopharyngeal Cancer Market - Segmented by Type of Therapy, and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • ID: 4591667
  • Report
  • Region: Global
  • 104 pages
  • Mordor Intelligence
1 of 5


  • Biocon
  • Bristol Myers Squibb
  • Eli Lilly And Company
  • Hoffmann-La Roche
  • Merck
  • Novartis
  • MORE
The global nasopharyngeal cancer market is projected to record a CAGR of approximately 2%, during the forecast period (2018-2023).

Growing Awareness towards Diagnosis and Treatment of Nasopharyngeal Cancer

There is a growing awareness towards diagnosis and treatment of nasopharyngeal cancer (NPC). Traditionally the public perception regarding nasopharyngeal cancer was very weak due to lack of government initiatives and low incidence rate of the disease. But, the rise in the number of NPC patients in North America region has changed this scenario. In the United States, nasopharyngeal carcinoma (NPC) is a rare malignancy of the upper digestive tract and has an incidence of less than 1 per 100,000. However, this disease has a well-documented regional and ethnic distribution such that individuals of Southern Chinese and Southeast Asian descent are up to 20-40 times more likely to develop NPC than individuals of European ethnicity. To increase the community awareness for ethnicities, which are predisposed to nasopharyngeal cancer, various primary healthcare centers have started awareness drive to increase the awareness on NPC. Consequently, greater adoption of NPC diagnosis and treatment is being witnessed, which is driving the growth of the global nasopharyngeal cancer market. Additionally, factors, like high prevalence of the NPC in regions of North America and Southern China, are also contributing to market growth.

Considerably Low Incidence Rate of Disease

Cancer of the nasopharynx is one of the most common cancers of neck and head, yet their overall global prevalence is considerably low. This is primarily due to the fact, that the incidence rate of the disease is not uniform across various regions and there is high concentration of nasopharyngeal cancer patients in some regions while almost close to zero prevalence in most other regions. For example, in Asia the Southeast region has the highest prevalence of nasopharyngeal cancer with prevalence rate of approximately 15 patients per 100,000 people. The prevalence rate in US and other regions of the world is less than 1 per 100,000 people. Consequently, this orphan status of the disease in overall global setting hinders the growth of the global nasopharyngeal cancer market, as drug manufacturers do not find the related drug development a lucrative business option due to overall low global incidence. Additionally, factors, like adverse side effects associated with current therapies and drugs indicated for nasopharyngeal cancer and lack of financial backing for research & development of blockbuster drugs are hindering the market growth.

Radiation Therapy has the largest market share

Radiation therapy forms the primary modality of treatment in nasopharyngeal cancer. It is closely followed by chemotherapy in terms of both market share and use-case in patients. Newer and advanced modalities of nasopharyngeal cancer treatment include combination of both radiotherapy and chemotherapy techniques. These treatment modalities are still in early clinical phases and will make commercial appearance late during the end of forecast period or maybe even after that.


Reasons to Purchase this Report
  • Current and future global nasopharyngeal cancer market outlook in the developed and emerging markets
  • Analyzing various perspectives of the market with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness fastest growth during the forecast period
  • Identifying the latest developments, market shares, and strategies employed by the major market players
  • 3 month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report

This report can be customized to meet your requirements.
Note: Product cover images may vary from those shown
2 of 5


  • Biocon
  • Bristol Myers Squibb
  • Eli Lilly And Company
  • Hoffmann-La Roche
  • Merck
  • Novartis
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product And Services
5.2.5 Competitive Rivalry Within The Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 High Prevalence in Regions, like North America, Southern China, and Canada
6.1.2 Growing Awareness Towards Diagnosis and Treatment of Nasopharyngeal Cancer
6.2 Market Restraints
6.2.1 Lack of Financial Backing for Research & Development of Blockbuster Drugs
6.2.2 Considerably Low Incidence Rate of the Disease
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Type of Therapy
7.1.1 Radiation Therapy External Beam Radiation Therapy Proton Therapy Stereotactic Radiosurgery Brachytherapy
7.1.2 Chemotherapy Cisplatin Fluorouracil (5-FU) Docetaxel Paclitaxel Gemcitabine
7.1.3 Others
7.2 By Geography
7.2.1 North America US Canada Mexico
7.2.2 Europe UK Germany France Italy Spain Rest of Europe
7.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
7.2.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
7.2.5 South America Brazil Argentina Rest of South America

8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, And Partnerships
8.3 New Products Launches

9. Key Players
9.1 Biocon
9.2 Bristol Myers Squibb
9.3 Eli Lilly and Company
9.4 Hoffman La-Roche
9.5 Merck
9.6 Novartis
9.7 Pfizer
9.8 Sanofi
*List Not Exhaustive

10. Future of The Market
Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Bristol Myers Squibb
  • Sanofi
  • Merck
  • Pfizer
  • Eli Lilly And Company
  • Novartis
  • Hoffmann-La Roche
  • Biocon
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4591667